

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner of Patents and Trademarks, Washington, D.C. 20231  
on MAY 17, 1999

By: Matthew Currell

11

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re National Phase of:

PCT/US96/18807 of

Mary Bending et al.

Application No.: Unassigned

Filed: September 11, 1998

For: THERAPEUTIC USES OF  
HUMANIZED ANTIBODIES  
AGAINST ALPHA-4 INTEGRIN

Examiner: Unassigned

Art Unit: Unassigned

PETITION FOR FILING DATE UNDER  
37 CFR §1.53Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

The above-captioned application was filed by express mail on September 11, 1998. The application is a national phase entry of International Application Number PCT/US96/18807, filed November 21, 1996. A copy of the filed papers is attached together with a copy of the postcard showing receipt thereof by the PTO stamped September 11, 1998.

Applicants have received no filing receipt or other communication from the PTO relating to the above-captioned application. Applicants therefore assume the present application has been lost at the PTO.

Applicants request the above-captioned application be given the filing date of September 11, 1998. Applicant further requests that the petition filed with the application relating to §371 status be considered, and the application be granted §371 status with respect to PCT/US/96/18807.






PATENT  
Attorney Docket No.:15270-001430US

Please charge the petition fee of \$130.00, if due, to the Deposit Account No.

20-1430. Please charge any additional fees or credit overpayment to the above Deposit Account.

This petition is submitted in duplicate.

Respectfully submitted,

  
Joe Liebeschuetz  
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (650) 326-2400  
Fax: (650) 326-2422  
JOL/nsc

PA 190172 v1